Non-Small Cell Lung Cancer

Response to Rapamycin Analogs but not PD-1 Inhibitors in PTEN-mutated Metastatic Non-small Cell Lung Cancer With High Tumor Mutational Burden

Response to Rapamycin Analogs but not PD-1 Inhibitors in PTEN-mutated Metastatic Non-small Cell Lung Cancer With High Tumor Mutational Burden

[Lung Cancer: Targets and Therapy] This case study demonstrates that genomic profiling may still benefit patients who fail checkpoint inhibitor therapy despite having high tumor mutational burden and PD-L1 positivity.

Multiple Treatment Modalities for Brain Metastasis in Patients With EGFR-mutant Non-small Cell Lung Cancer

Multiple Treatment Modalities for Brain Metastasis in Patients With EGFR-mutant Non-small Cell Lung Cancer

[OncoTargets and Therapy] Management of brain metastases in patients with EGFR-mutant NSCLC is controversial. In this study, researchers find combination and sequential treatment with EGFR-TKIs, chemotherapy, and radiotherapy is beneficial.

Nabilone Improves Cancer-Associated Anorexia in Lung Cancer

Nabilone Improves Cancer-Associated Anorexia in Lung Cancer

By

Researchers assessed the efficacy of nabilone for improving symptoms of anorexia in patients with NSCLC. In addition, patient appetite, quality of life, and nutritional status were also assessed.

Treatment and Outcomes of Non-small-cell Lung Cancer Patients With High Comorbidity

Treatment and Outcomes of Non-small-cell Lung Cancer Patients With High Comorbidity

[Cancer Management and Research] The presence of comorbidities is thought to play a significant role in the decision to treat patients with NSCLC, and this impacts survival.

Osimertinib improves progression-free survival in EGFR-mutated non-small-cell lung cancer: The FLAURA trial

1. Osimertinib demonstrated a significantly longer duration of progression-free survival compared to standard of care epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) in patients with untreated EGFR-mutated locally-advanced or metastatic non-small-cell lung cancer (NSCLC). 2. Osimertinib treated patients had fewer grade 3 or higher adverse events compared to patients treated with standard EGFR-TKI therapy. []

Surgery May Be Superior to Stereotactic Body RT for Early Stage Non-small Cell Lung Cancer

Surgery May Be Superior to Stereotactic Body RT for Early Stage Non-small Cell Lung Cancer

By

SBRT provides excellent local control and an adequate safety profile, but there is a lack of data comparing SBRT to resection among patients eligible for surgery.

Nab-paclitaxel/carboplatin Induction in Squamous NSCLC: Longitudinal Quality of Life While on Chemotherapy

Nab-paclitaxel/carboplatin Induction in Squamous NSCLC: Longitudinal Quality of Life While on Chemotherapy

[Lung Cancer: Targets and Therapy] Researchers examine the affect of first-line nab-paclitaxel plus carboplatinon QoL for patients with advanced non-small cell lung cancer.

Gefitinib Adjuvant Therapy Prolonged Disease-Free Survival in EGFR-Mutant NSCLC

Gefitinib Adjuvant Therapy Prolonged Disease-Free Survival in EGFR-Mutant NSCLC

By

Results of this randomized, phase 3 study comparing oral gefitinib with IV vinorelbine plus cisplatin revealed the effect of these regimens on disease-free survival in patients with exon 19 deletion or exon Leu585Arg NSCLC.

Alectinib Granted FDA Approval as First-line Therapy for <i>ALK</i>-positive NSCLC

Alectinib Granted FDA Approval as First-line Therapy for ALK-positive NSCLC

By

Approval was based on results from ALEX, for which researchers randomly assigned 303 patients with ALK-positive NSCLC not previously treated with systemic therapy to receive alectinib or crizotinib.

Yoga Programs May Improve Quality of Life for Patients with NSCLC and Their Caregivers

Yoga Programs May Improve Quality of Life for Patients with NSCLC and Their Caregivers

By

This study evaluated the feasibility and potential efficacy of a yoga intervention for patients with NSCLC and their caregivers.

Language Barrier, Patient Ethnicity Do Not Delay Hospital Treatment in NSCLC

Language Barrier, Patient Ethnicity Do Not Delay Hospital Treatment in NSCLC

By

Impact of language barrier and patient ethnicity on time interval from diagnosis to treatment for patients with NSCLC was measured at a public hospital and a private hospital.

Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC

Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC

By

Two phase 3 studies reveal the clinical benefit, safety profile, and overall survival of nivolumab and docetaxel for patients with squamous and nonsquamous NSCLC.

Osimertinib in the Treatment of Non-small Cell Lung Cancer: Design, Development and Place in Therapy

Osimertinib in the Treatment of Non-small Cell Lung Cancer: Design, Development and Place in Therapy

[Lung cancer: Targets and Therapy] This research examines clinical data from Phase I-III trials of osimertinib, discusses mechanisms of resistance to osimertinib, and provides an outlook for the use of osimertinib and novel therapeutic combinations to improve EGFR-mutated NSCLC outcomes.

Radiation Prior to Chemotherapy Prolongs Progression-Free Survival in NSCLC

Radiation Prior to Chemotherapy Prolongs Progression-Free Survival in NSCLC

By

Researchers present findings of a phase 2 study that compared PFS when SBRT is administered prior to maintenance chemotherapy in patients with limited metastatic NSCLC vs chemotherapy alone. Data was presented at ASTRO 59th Annual Meeting.

Adjuvant Durvalumab Therapy May Prolong Progression-free Survival in NSCLC

Adjuvant Durvalumab Therapy May Prolong Progression-free Survival in NSCLC

By

Patients with stage III NSCLC have a poor median PFS of 8 months despite achieving a good response to the current standard of care of platinum-based double chemotherapy with concurrent radiotherapy.

Cannabis Reduces Response Rate to Immunotherapy for Cancer

Cannabis Reduces Response Rate to Immunotherapy for Cancer

By

Investigators report that administering cannabis to patients with cancer undergoing immunotherapy was found to lower the response rate to therapy but had no effect on PFS or OS, in an oral presentation at ESMO 2017 Congress.

Survival Predictions for NSCLC Accurate With the Lung Cancer Prognostic Index

Survival Predictions for NSCLC Accurate With the Lung Cancer Prognostic Index

By

The Lung Cancer Prognostic Index (LCPI) provides additional relevant prognostic data for patients with NSCL and may lead to better outcomes.

Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics

Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics

By

An analysis of rates at certain milestones in clinical trials of treatments for mNSCLC suggests these rates reflect end point results for immunotherapies vs targeted and conventional therapies.

New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer

New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer

By

Doses May Be Adjusted for Treating NSCLC Patients

Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC

Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC

By

Phase 3 clinical trial results show fewer adverse effects and longer survival with alectinib compared with crizotinib in patients with treatment-naïve ALK-positive NSCLC.

Navigating the Non-small Cell Lung Cancer Patient: CT Lung Cancer Screening Development

Navigating the Non-small Cell Lung Cancer Patient: CT Lung Cancer Screening Development

By

Developing a lung cancer screening program involves a number of challenges, including identifying patients in need of screening, patient follow-up, and community support.

Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab

Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab

By

A significantly higher 5-year survival rate was seen in a small subset of patients with NSCLC treated with nivolumab.

Radiation Therapy for Locally Advanced NSCLC Linked to Cardiac Events

Radiation Therapy for Locally Advanced NSCLC Linked to Cardiac Events

By

Risk for cardiac events linked to RT for locally advanced NSCLC, especially in patients with a history of cardiac disease or receiving higher RT doses.

CTCs Promising as Biomarker to Identify Lung Cancer Recurrence

CTCs Promising as Biomarker to Identify Lung Cancer Recurrence

By

Prospective pilot study demonstrates accuracy of circulating tumor cells as a biomarker indicating lung cancer recurrence.

Proportion of Never-Smokers With NSCLC Is on the Rise

Proportion of Never-Smokers With NSCLC Is on the Rise

By

A study of a large, diverse patient population appears to show an increasing incidence of lung cancer in patients who have never smoked tobacco.

NSCLC: Pathway Navigation Program Lowers Costs of Care

NSCLC: Pathway Navigation Program Lowers Costs of Care

By

A clinical pathways navigation program for patients with non-small cell lung cancer significantly reduced cost of care while preserving clinical outcomes.

FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC

FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC

By

Ceritinib has been granted Priority Review as a first-line treatment for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer.

Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments

Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments

By

Elderly with NSCLC have lower incidence of esophagitis, can tolerate aggressive radiation therapy.

New Study Shows Standard of Care for NSCLC Patients Leads to Improved Overall Survival

New Study Shows Standard of Care for NSCLC Patients Leads to Improved Overall Survival

By

There are a growing number of NSCLC patients with advanced disease who are opting to forgo treatment despite the fact that receiving standard of care treatment leads to a higher OS.

First-line Ceritinib Improves PFS vs Chemo in Advanced ALK-rearranged NSCLC

First-line Ceritinib Improves PFS vs Chemo in Advanced ALK-rearranged NSCLC

By

Ceritinib is a kinase inhibitor indicated for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib; in this study, researchers determined the efficacy of ceritinib in patients with untreated ALK-rearranged NSCLC.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs